|
**Overview**: **Hepatitis C Monitoring Profile****Introduction**: The Hepatitis C Monitoring Profile is a diagnostic tool designed to monitor hepatitis C infection using serum samples. Associated with conditions like chronic hepatitis C and liver fibrosis, these disorders present with jaundice, fatigue, and severe complications if untreated, particularly in individuals with suspected liver disease. Per the 2023 Serology and Molecular Pathology guidelines, the test employs serology and molecular pathology with immunoassay and PCR technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for hepatitis monitoring in clinical settings. This diagnostic falls under hepatitis monitoring and targets individuals with confirmed or suspected hepatitis C, addressing the challenge of accurate viral and liver function assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: Hep C Mon Pfl.**FDA Status**: FDA approved, CLIA certified for serology and molecular pathology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1980s by virology labs, this test advanced hepatitis C monitoring.**Purpose**: The test screens for 29 parameters including Anti-HCV to guide hepatitis C assessment, assess viral load and liver function, and inform treatment and prevention strategies.**Test Parameters**: 1. Anti-HCV, 2. HCV RNA Quantitative, 3. HCV Genotype, 4. Total Bilirubin, 5. Direct Bilirubin, 6. AST, 7. ALT, 8. ALP, 9. Total Protein, 10. Albumin, 11. Globulin, 12. GGT, 13. Prothrombin Time, 14. INR, 15. Creatinine, 16. Urea, 17. Sodium, 18. Potassium, 19. Platelet Count, 20. AFP, 21. FibroTest, 22. Haptoglobin, 23. Ceruloplasmin, 24. Ferritin, 25. Alpha-1-Antitrypsin, 26. IL-28B, 27. HCV Core Antigen, 28. Transferrin, 29. Apolipoprotein A1.**Pretest Condition**: No fasting required; patients should report jaundice, fatigue, or recent liver symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on jaundice, fatigue, prior liver reactions, or family history of hepatitis, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated hepatitis C including cirrhosis, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using immunoassay and PCR and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent antiviral use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible hepatitis C progression, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in hepatology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Liver biopsy or imaging for confirmation.**Test Limitations**: The test may produce false negatives in early infection stages or false positives in sample degradation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Serology and Molecular Pathology Guidelines 2023, Journal of Hepatology 2024, Biochemistry 2025. |
